Compass Therapeutics (CMPX) Operating Income (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Operating Income data on file, last reported at -$20.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 12.99% year-over-year to -$20.3 million; the trailing twelve-month figure through Mar 2026 stood at -$75.2 million (down 21.59% YoY), and the FY2025 full-year result was -$72.8 million, down 28.63% from the prior year.
• Operating Income fell to -$20.3 million in Q1 2026, from -$18.0 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$7.2 million in Q1 2022 to a low of -$21.1 million in Q2 2025.
• A 5-year average of -$14.2 million and a median of -$13.3 million in 2023 frame the typical range for Operating Income.
• Across the five-year window, Operating Income sank 115.2% in 2022 and advanced 5.33% in 2023, its largest moves.
• Tracing CMPX's Operating Income over 5 years: stood at -$12.9 million in 2022, then fell by 19.44% to -$15.4 million in 2023, then dropped by 7.67% to -$16.6 million in 2024, then dropped by 8.54% to -$18.0 million in 2025, then dropped by 12.83% to -$20.3 million in 2026.
• Business Quant data shows CMPX's Operating Income at -$20.3 million in Q1 2026, -$18.0 million in Q4 2025, and -$15.8 million in Q3 2025.